Methods in Pharmacoepidemiology / Analytical Methods

((A-172)) (A-172) Iterative Causal Survival Forest: A Novel Subgrouping Algorithm for Survival Data Allowing for Censoring

((A-173)) (A-173) Recalculating Propensity Score or Not for Subgroup Analysis in Propensity Score Matching and Inverse Probability of Treatment Weighting: A Monte Carlo Simulation Study

((A-174)) (A-174) Evaluating the Robustness of Propensity Score Methods in Survival Analysis Under Sample Size Imbalance: A Monte Carlo Simulation

((A-175)) (A-175) Interpretable Machine Learning Models: Describing Treatment Patterns of Healthcare Providers Selecting Rheumatoid Arthritis Therapies to Evaluate Treatment Policies

((A-176)) (A-176) Performance of Machine Learning Predictions of Overall Survival After Multiple Imputations for Features Based on Absolute Non-Missing Degrees

((A-177)) (A-177) An Alternative to Non-Responder Imputation for Study Participants with Missing Outcomes in Single-Arm Drug Effectiveness Studies: A Case Study in the CorEvitas Psoriasis Registry

((A-178)) (A-178) The association between fibrate use and the risk of diabetic peripheral vascular disease in patients with type 2 diabetes mellitus: A nested case-control study

((A-179)) (A-179) Transfer Learning Strategies for Addressing Class Imbalance in Drug Adverse Reaction Prediction: Simulation and Empirical Analysis

((A-180)) (A-180) Machine Learning Methods for Predicting Adverse Drug Events: A Systematic Review

((A-181)) (A-181) Explainable Artificial Intelligence for Predicting Chemotherapy Toxicity: A Machine Learning Approach Using Pooled Clinical Trial Data

((A-182)) (A-182) Validity of High-Throughput Pharmacoepidemiologic Methods Using Electronic Healthcare Databases for Drug Repurposing Research: Application to Systemic Lupus Erythematosus

((A-183)) (A-183) Why We Should Be Prioritizing the Average Treatment Effect on the Treated Over Other Estimands When Evaluating Medical Product Safety

((A-184)) (A-184) Potential for Extreme Bias Due to Outcome Misclassification in Relative Measures of Effect for Rare Time-to-Event Outcomes

((A-185)) (A-185) Evaluating Sequence Symmetry Analysis Across Six European Healthcare Databases

((A-187)) (A-187) Using a Random Slope Model to Evaluate the Association Between Initial High/Low Opioid Dosage and Kidney Function Change Over One Year Post-Surgical Discharge

((A-188)) (A-188) Group-Based Trajectory Models to Identify Potential Reasons for Treatment Switch Among Patients with Neovascular Age-Related Macular Degeneration (nAMD)

((A-189)) (A-189) Studying When to Add Biological Therapy to Cytotoxic Therapy in Advanced Cancer Care Using Real World Data (RWD): Challenges and Solutions to Avoid Biases that Generate Immortal Time

((A-190)) (A-190) Using causal trees to explore the heterogeneity of effects

((A-191)) (A-191) Healthcare Resource Utilization Disruptions During the COVID-19 Era and Methodological Considerations: A Review

((A-192)) (A-192) Title: Fostering Creativity in AI: Insights from a Datathon Tackling HIV Screening Challenges

((A-193)) (A-193) Exploring methods for identifying heterogenous treatment effects (HTEs) for second-line type 2 diabetes medications and cardiovascular outcomes

((A-194)) (A-194) Intercurrent Events in Estimands: Where RWE meets RCTs

((A-195)) (A-195) Estimating artificial censoring weights for clone censor weighting studies: techniques and lessons learned